Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.
Sun Pharmaceutical Industries Ltd has announced the introduction of FluGuard (Favipiravir 200 mg) at a price of ₹35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.
If you want to change selection, open document below and click on "Move attachment"
Unknown titlepatients with mild to moderate Covid-19 disease. Share Article 0 PRINT A A A The stocks of the medicine will be available in the market from this week, the company said. | Photo Credit: REUTERS <span>Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease. Sun Pharmaceutical Industries Ltd has announced the introduction of FluGuard (Favipiravir 200 mg) at a price of ₹35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Glenmark’s FabiFlu is available at ₹75 a tablet as the company recently brought down the price from ₹103 a tablet during the time of introduction. Favipiravir is the only oral anti-vira Summary
| status | not read | | reprioritisations | |
|---|
| last reprioritisation on | | | suggested re-reading day | |
|---|
| started reading on | | | finished reading on | |
|---|
Details